Harvest Management LLC bought a new position in shares of Livongo Health (NASDAQ:LVGO) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 42,927 shares of the company’s stock, valued at approximately $6,012,000. Livongo Health comprises 6.6% of Harvest Management LLC’s investment portfolio, making the stock its 4th largest position.
Several other hedge funds have also made changes to their positions in the company. Parametric Portfolio Associates LLC acquired a new position in shares of Livongo Health in the 1st quarter valued at about $602,000. Nuveen Asset Management LLC raised its position in Livongo Health by 172.6% during the 1st quarter. Nuveen Asset Management LLC now owns 234,260 shares of the company’s stock worth $6,684,000 after buying an additional 148,322 shares during the last quarter. Alliancebernstein L.P. raised its position in Livongo Health by 321.2% during the 1st quarter. Alliancebernstein L.P. now owns 69,914 shares of the company’s stock worth $1,995,000 after buying an additional 53,314 shares during the last quarter. Deutsche Bank AG raised its position in Livongo Health by 240.4% during the 1st quarter. Deutsche Bank AG now owns 18,066 shares of the company’s stock worth $515,000 after buying an additional 12,759 shares during the last quarter. Finally, Legal & General Group Plc raised its position in Livongo Health by 387.2% during the 1st quarter. Legal & General Group Plc now owns 14,396 shares of the company’s stock worth $380,000 after buying an additional 11,441 shares during the last quarter. Institutional investors own 41.67% of the company’s stock.
A number of equities analysts have commented on the stock. Royal Bank of Canada upped their price objective on shares of Livongo Health from $53.00 to $120.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 8th. Stifel Nicolaus cut shares of Livongo Health from a “buy” rating to a “hold” rating and set a $137.00 price target on the stock. in a research note on Monday, August 24th. Benchmark cut shares of Livongo Health from a “buy” rating to a “hold” rating in a research note on Friday, August 7th. Needham & Company LLC cut shares of Livongo Health from a “buy” rating to a “hold” rating in a research note on Thursday, August 6th. Finally, KeyCorp raised their price target on shares of Livongo Health from $85.00 to $105.00 in a research note on Tuesday, July 7th. Seven research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Livongo Health currently has a consensus rating of “Buy” and a consensus target price of $94.94.
LVGO traded up $3.01 during trading on Monday, reaching $141.92. The company had a trading volume of 15,468 shares, compared to its average volume of 3,015,559. The firm’s 50-day simple moving average is $135.34 and its 200 day simple moving average is $94.01. The company has a market cap of $14.11 billion, a price-to-earnings ratio of -338.80 and a beta of 1.77. Livongo Health has a 12-month low of $18.76 and a 12-month high of $151.05. The company has a debt-to-equity ratio of 0.69, a quick ratio of 19.51 and a current ratio of 19.88.
Livongo Health (NASDAQ:LVGO) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $0.11 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.17. Livongo Health had a negative return on equity of 4.86% and a negative net margin of 12.76%. The firm had revenue of $91.90 million for the quarter, compared to analysts’ expectations of $86.68 million. During the same quarter last year, the business posted ($0.46) EPS. Livongo Health’s revenue was up 124.1% on a year-over-year basis. On average, sell-side analysts expect that Livongo Health will post -0.05 EPS for the current year.
In related news, CFO Lee Shapiro sold 5,734 shares of Livongo Health stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $132.53, for a total transaction of $759,927.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Zane M. Burke sold 49,115 shares of Livongo Health stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $124.50, for a total value of $6,114,817.50. Following the sale, the chief executive officer now directly owns 964,838 shares of the company’s stock, valued at $120,122,331. The disclosure for this sale can be found here. Insiders sold 691,865 shares of company stock worth $86,180,389 in the last three months. Insiders own 13.00% of the company’s stock.
Livongo Health Profile
Livongo Health, Inc provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications.
Recommended Story: Trading Stocks – What are percentage gainers?
Want to see what other hedge funds are holding LVGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Livongo Health (NASDAQ:LVGO).
Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.